期刊文献+

奥沙利铂联合5-FU、LV方案治疗消化道癌72例临床观察 被引量:3

下载PDF
导出
摘要 目的评价奥沙利铂与氟尿嘧啶、亚叶酸钙治疗术后消化道癌的疗效和安全性。方法共收治消化道癌患者72例,术后采用L—OHP 130mg/m^2,静滴2小时。1~5天LV 200mg/m^2,静滴2小时,5-Fu 500mg/m^2,静滴4小时。每月重复1次,治疗3个周期后评价疗效。结果完全缓解(CR)8例(11%),部分缓解(PR)40例(55.7%),无变化(NC)24例(33.3%),总有效率66.7%。副反应主要为感觉神经毒性及恶心、呕吐。结论L-OHP联合5-Fu、LV治疗晚期消化道癌疗效肯定,毒副反应能耐受,值得临床推广应用。
作者 付朝江 崔明
出处 《西部医学》 2010年第5期822-823,共2页 Medical Journal of West China
  • 相关文献

参考文献9

  • 1Folprecht G.Kohne CH.The role of new agengts in the treatment of colorectal caner[J].Oncolo gy,2004,66(1):1-17.
  • 2应杰儿,钟海均,冯海洋.FOLFOX4方案治疗晚期大肠癌的临床观察[J].肿瘤防治杂志,2005,12(18):1423-1424. 被引量:28
  • 3Louvet C,Degramant A.Role and value of oxaliplatin in metastatic col-orectal cancers[J].Rev Med Interne,1997,18(4):368-371.
  • 4De Gramont A,Bosset JF,Milan C,et al.Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-doseleucovorin and fluorouracil bolus plus continuous infusion for advaneedcolorectal cancer:a French intergroup study[J].J Clin Oncol,1997,15(2):808-815.
  • 5林万隆,陈强.奥沙利铂的药理作用及临床应用[J].中国肿瘤临床,2000,27(11):872-874. 被引量:333
  • 6卓越.新编临床药物实用手册[M].北京:科学出版社,2004:256-266.
  • 7Raymond E,Faivre S Chaney S,et al.Cellular and molecularpharmacology of oxaliplatin[J].MolCancerTher,2002,1(3):227-235.
  • 8De Gramont,Figer A,SeymonrM,et al.Leu eonvorin and fluorouracilwith or without oxaliplatin as fit-line treatment in advanced colorectal[J].J Clin Oncol.2000,18:2938-2947.
  • 9Ahned FE.Molecular markers that predict response colon cancer therapy[J].Expert Rev Mol Diagn,2005,5(3):353-375.

二级参考文献12

  • 1张文,许立功.晚期结直肠癌的化疗进展[J].中国癌症杂志,2004,14(4):378-382. 被引量:25
  • 2陆仰东.国产奥沙利铂为主的联合化疗治疗51例晚期大肠癌疗效观察[J].中国肿瘤临床,2004,31(24):1401-1403. 被引量:5
  • 3Li X M,Arch Toxicol,1998年,72卷,9期,574页
  • 4Goldstein D, Mitchell P, Michal M, et al. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer Patients[J]. Br J Cancer,2005, 92(5) :832-837.
  • 5Hsuen Lim E, Seng Cheong Lim R, Seng Wu T, et al. Oxaliplatin/fluorouracil/leucovorin in advanced colorectal carcinoma:an asian experience[J]. Pann Pharmacother,2003,37(12) :1909-1912.
  • 6Kemeny N, Garay C A, Gurtler J, et al. Randomized multicenter phase Ⅱ trial of bolus plus in FU sional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer [J]. J Clin Oncol,2005,23(1) :248-252.
  • 7Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics,2002[J]. CA Cancer J Clin, 2005, 55(2) :74-108.
  • 8Rixe O, Ortuzar W,Alvarez M, et al. Oxaliplatin,tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug resistant celllines and in the cell lines of the National Cancer Institute ' s Anticancer Drug Screen panel[J]. Biochem Pharmacol, 1996,52 (12): 1855 -1865.
  • 9Kuebler J P,de Gramont A. Recent Experience With Oxaliplatin or lrinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer[J]. Semin Oncol,2004,30(4 Suppl 15) :40-47.
  • 10Simpson D, Dunn C, Curran M. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer [J]. Drugs, 2003,63(19) :2127-2156.

共引文献354

同被引文献17

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部